Literature DB >> 19815009

Glutamate, excitotoxicity, and programmed cell death in Parkinson disease.

W Michael Caudle1, Jing Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19815009     DOI： 10.1016/j.expneurol.2009.09.027

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


× No keyword cloud information.
  38 in total

1.  Head injury, α-synuclein Rep1, and Parkinson's disease.

Authors:  Samuel M Goldman; Freya Kamel; G Webster Ross; Sarah A Jewell; Grace S Bhudhikanok; David Umbach; Connie Marras; Robert A Hauser; Joseph Jankovic; Stewart A Factor; Susan Bressman; Kelly E Lyons; Cheryl Meng; Monica Korell; Diana F Roucoux; Jane A Hoppin; Dale P Sandler; J William Langston; Caroline M Tanner
Journal:  Ann Neurol       Date:  2012-01       Impact factor: 10.422

2.  Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.

Authors:  Iris Y Kim; Éilis J O'Reilly; Katherine C Hughes; Xiang Gao; Michael A Schwarzschild; Marjorie L McCullough; Marian T Hannan; Rebecca A Betensky; Alberto Ascherio
Journal:  Mov Disord       Date:  2018-01-10       Impact factor: 10.338

3.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

4.  An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

Authors:  Aditiben Patel; Giuseppe V Toia; Kalea Colletta; Brinda Desai Bradaric; Paul M Carvey; Bill Hendey
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

5.  Facile fabrication of flexible glutamate biosensor using direct writing of platinum nanoparticle-based nanocomposite ink.

Authors:  Tran N H Nguyen; James K Nolan; Hyunsu Park; Stephanie Lam; Mara Fattah; Jessica C Page; Hang-Eun Joe; Martin B G Jun; Hyungwoo Lee; Sang Joon Kim; Riyi Shi; Hyowon Lee
Journal:  Biosens Bioelectron       Date:  2019-01-31       Impact factor: 10.618

6.  Functional NMDA receptors with atypical properties are expressed in podocytes.

Authors:  Marc Anderson; Jae Mi Suh; Eun Young Kim; Stuart E Dryer
Journal:  Am J Physiol Cell Physiol       Date:  2010-08-25       Impact factor: 4.249

7.  Peroxiredoxin 5 Inhibits Glutamate-Induced Neuronal Cell Death through the Regulation of Calcineurin-Dependent Mitochondrial Dynamics in HT22 Cells.

Authors:  Mi Hye Kim; Hong Jun Lee; Sang-Rae Lee; Hyun-Shik Lee; Jae-Won Huh; Yong Chul Bae; Dong-Seok Lee
Journal:  Mol Cell Biol       Date:  2019-09-27       Impact factor: 4.272

Review 8.  Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective.

Authors:  Haydeh Payami; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 9.  Kynurenines in Parkinson's disease: therapeutic perspectives.

Authors:  Dénes Zádori; Péter Klivényi; József Toldi; Ferenc Fülöp; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-08-20       Impact factor: 3.575

Review 10.  The delta-opioid receptor and Parkinson's disease.

Authors:  Jin-Zhong Huang; Yi Ren; Yuan Xu; Tao Chen; Terry C Xia; Zhuo-Ri Li; Jian-Nong Zhao; Fei Hua; Shi-Ying Sheng; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2018-08-03       Impact factor: 5.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.